Diabetes Research and Clinical Practice
Volume 74, Issue 2, Supplement , Pages S41-S50 , 30 November 2006

The relationship between genetic and haemodynamic factors in diabetic nephropathy (DN): Case–control study in type 1 diabetes mellitus (T1DM)

  • M.V. Shestakova

      Affiliations

    • Endocrinology Research Center RAMS, Moscow, Russia
    • Corresponding Author InformationCorresponding author.
    • ,
  • O.K. Vikulova

      Affiliations

    • Endocrinology Research Center RAMS, Moscow, Russia
    • ,
  • N.M. Gorashko

      Affiliations

    • National Research Center “GosNII genetika”, Moscow, Russia
    • ,
  • O.E. Voronko

      Affiliations

    • National Research Center “GosNII genetika”, Moscow, Russia
    • ,
  • N.B. Babunova

      Affiliations

    • National Research Center “GosNII genetika”, Moscow, Russia
    • ,
  • V.V. Nosikov

      Affiliations

    • National Research Center “GosNII genetika”, Moscow, Russia
    • ,
  • I.I. Dedov

      Affiliations

    • Endocrinology Research Center RAMS, Moscow, Russia

References 

  1. Pirart J. Diabetes mellitus and its degenerative complications: a prospective study of 4400 patients observed between 1947 and 1973. Diabetes Care. 1978;1:168–188
  2. Krolewski AJ, Warram JH, Rand LI, Kahn CR. Epidemiologic approach to the etiology of type I diabetes mellitus and its complications. N. Engl. J. Med. 1987;317:1390
  3. M. Marre, Diabetic renal disease: genetic pattern and risk factors, in: Reducing the Burden of Diabetes Journal ISSN (1996) (Issue 8) 5–8.
  4. Bloem LJ, Manatunga AK, Tewksburi DA. The serum angiotensinogen concentration and variants of angiotensinogen gene in white and black children. J. Clin. Invest. 1995;95:948–953
  5. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, et al. Linkage of the angiotensinogen gene to essential hypertension. N. Engl. J. Med. 1994;330:1629–1633
  6. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Covol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J. Clin. Invest. 1990;86:1343–1346
  7. Fornage M, Turner ST, Sing CF, Boerwinkle E. Variation at the M235T locus of angiotensinogen gene and essential hypertension: a population-based case control study from Rochester, Minnesota. Hum. Genet. 1995;96:295–300
  8. Hingorani AD, Brown MJ. A simple molecular assay for the 1166 variant of the angiotensin II type 1 receptor gene. Biochem. Biophys. Res. Commun. 1995;15:725–729
  9. Cohen RA. The role of nitric oxide and other endothelium derived vasoactive substances in vascular disease. Cardiovasc. Dis. 1995;38:W5–W28
  10. Bakris GL. Maximizing cardio-renal benefits: achieve blood pressure goals. J. Clin. Hypertens. 1999;1:141–148
  11. Lasarus JM, Bourgoignie JJ, Buuckalew VM, Greene T, Levey AS, Milas NC, et al. Achievement and safety of a low BP goal in chronic renal disease. The modification of diet in renal disease study group. Hypertension. 1997;29:641–650
  12. R.G. Nelson, W.C. Knowler, D.J. Pettit, P.H. Bennett, Kidney disease in diabetes, in: Diabetes in America, National Institutes of Health Publication No. 95-1468, 2nd ed, National Institutes of Health, Bethesda, MD, 1995, pp. 349–400.
  13. Anderson A. Role of local and systemic angiotensin in diabetic renal disease. Kidney Int. 1997;63:S107–S110
  14. Johns MB, Paulus-Thomas JE. Purification of human genomic DNA from whole blood using proteinase K treatment followed by phenol–chloroform extraction. Anal. Biochem. 1989;180:276–278
  15. Miyahara K, Kawamoto T, Sase K. Cloning and structural characterization of the human endothelial nitric-oxide-synthase gene. Eur. J. Biochem. 1994;223:719–726
  16. D.J.R. Hutchon, Calculator for confidence intervals for odds ratio unmatched case control study, http://www.hutchon.net/Confid OR.htm.
  17. Rasmussen LM, Ledet T. Aortic atherosclerosis in diabetes mellitus is associated with an insertion/deletion polymorphism in the angiotensin I-converting enzyme gene. No relation between the polymorphism and aortic collagen content. Diabetologia. 1996;39:696–700
  18. Tabaei BP, Al-Kassab AS, Ilag LL, Zawacki CM, Herman WH. Does microalbuminuria predict diabetic nephropathy?. Diabetes Care. 2001;24:1560–1566
  19. Rogus JJ, Warram JH, Krolewski AS. Genetic studies of late diabetic complications. The overlooked importance of diabetes duration before complication onset. Diabetes. 2002;51:1655–1662
  20. Doria A, Warram JH, Krolewski AS. Genetic predisposition to diabetic nephropathy: evidence for a role of the angiotensin I-converting enzyme gene. Diabetes. 1994;43:690–695
  21. Fujisawa T, Ikegami H, Kawaguchi Y, Hamada Y, Ueda H, Shintani M, et al. Meta-analysis of association of insertion/deletion polymorphism of angiotensin I-converting enzyme gene with diabetic nephropathy and retinopathy. Diabetologia. 1998;41:47–53
  22. Marre M, Bernadet P, Gallois Y, Savagner F, Guyene TT, Hallab M, et al. Relationships between angiotensin I-converting enzyme gene polymorphism, plasma levels, and diabetic retinal and renal complications. Diabetes. 1994;43:384–388
  23. Marre M, Jeunemaitre X, Gallois Y, Rodier M, Chatellier G, Sert C, et al. Contribution of genetic polymorphism in the renin-angiotensin system to the development of renal complications in insulin-dependent diabetes: (GENEDIAB) Study Group. J. Clin. Invest. 1997;99:1585–1595
  24. Miller JA, Scholey JW, Thai K, Pei PCY. Angiotensin converting enzyme gene polymorphism and renal hemodynamic function in early diabetes. Kidney Int. 1997;51:119–124
  25. Baboolal K, Ravine D, Danials J, Williams N, Holmans P, Coles GA, et al. Association of angiotensin-I converting enzyme gene deletion polymorphism with early onset of ESRF in PCD1 adult polycystic kidney disease. Kidney Int. 1997;52:607–613
  26. Perez-Oller L, Torra R, Badenas C, Mila M, Darnell A. Influence of the ACE gene polymorphism in the progression of renal failure in autosomal dominant polycystic kidney disease. Am. J. Kidney Dis. 1999;34:273–278
  27. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Ricard S, et al. Angiotensin-II type 1 receptor gene polymorphism and diabetic microangiopathy. Nephrol. Dial. Transplant. 1996;11:1019–1023
  28. Tarnow L, Cambien F, Rossing P, Nielsen FS, Hansen BV, Ricard S, et al. Angiotensinogen gene polymorphisms in IDDM patients with diabetic nephropathy. Diabetes. 1996;45:367–369
  29. Sugimoto H, Shikata K, Matsuda M, Kushiro M, Hayashi Y, Hiragushi K, et al. Increased expression of endothelial cell nitric oxide synthase (ecNOS) in afferent and glomerular endothelial cells is involved in glomerular hyperfiltration of diabetic nephropathy. Diabetologia. 1998;41:1426–1434
  30. Van Ittersam FJ, De Man AM, Thijssen S. Genetic polymorphisms of the renin-angiotensin system and complications of insulin-dependent diabetes mellitus. Nephrol. Dial. Transplant. 2000;15:1000–1007
  31. Vasku A, Soucek M, Znojil V, Rihacek I, Tschoplova S, Strelcova L, et al. Angiotensin I-converting enzyme and angiotensinogen gene interaction and prediction of essential hypertension. Kidney Int. 1998;53:1479–1482
  32. Wang XL, Mahaney MC, Siew A. Genetic contribution of the endothelial constitutive nitric oxide synthase gene to plasma nitric oxide levels. Arteriorscler. Thromb. Vasc. Biol. 1997;17:3147–3153
  33. Doria A, Onuma T, Gearin G, Freire MBS, Warram J, Krolewski A. Angiotensinogen polymorphism M235T, hypertension and nephropathy in insulin dependent diabetes. Hypertension. 1996;27:1134–1139
  34. Alaveras AG, Thomas SM, Sagriotis A, Viberti GC. Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. Nephrol. Dial. Transpl. 1997;12:71–74
  35. Colhoun HM, et al. Risk factors for renal failure: the WHO multinational study of vascular disease in diabetes. Diabetologia. 2001;44:S46–S53
  36. Mogensen CE. Microalbuminuria, blood pressure and diabetic renal disease: origin and development of ideas. Diabetologia. 1999;42:263–285
  37. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Jilius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomized trial: HOT Study Group. Lancet. 1998;351:1755–1762
  38. Shestakova MV, Vikulova OK, Nosikov VV. Role of genetic factors and arterial hypertension in development and progression of diabetic nephropathy (DN) in type 1 diabetes. Diabetes. 2005;54:795
  39. Turner R, et al. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UK Prospective Diabetes Study. BMJ. 1998;317:703–713
  40. Kondratiev YY, Shestakova MV, Shamkhalova MS, Tchugunova LA, Gorashko NM, Chistyakov DA, et al. Use of extreme phenotypes in association study of genetic susceptibility to diabetic nephropathy in IDDM patients. Diabetologia. 1998;41:A293
  41. Wang XL, Sim AS, Badenhop RF, McCredie RM, Wilcken DE. A smoking-dependent risk of coronary artery disease associated with a polymorphism of the endothelial nitric oxide synthase gene. Nat. Med. 1996;2:41–45

PII: S0168-8227(06)00281-6

doi: 10.1016/j.diabres.2006.06.013

Diabetes Research and Clinical Practice
Volume 74, Issue 2, Supplement , Pages S41-S50 , 30 November 2006

Article Tools

* Image Usage & Resolution